The Testing Gap That Cannabis Legalization Created
For alcohol, law enforcement has a clear, validated, court-accepted tool: the breathalyzer. Blood alcohol concentration correlates reliably with impairment, and evidentiary standards are well-established across all jurisdictions.
Cannabis is different — and the science confirms it. Blood THC concentration does not track impairment the way BAC does. Regular cannabis users can have elevated THC levels days after last use, long after any functional impairment has cleared. Conversely, acute impairment can occur at THC concentrations that appear "low" in blood testing.
The result: law enforcement is left relying on officer observation and Standardized Field Sobriety Tests (SFSTs) designed for alcohol — not cannabis. Prosecutors face challenges sustaining charges. Defense attorneys routinely challenge the absence of objective data.
ClearGazeTest addresses the gap by measuring neurological function directly — what the brain is actually doing — using oculomotor biomarkers that respond to all impairing substances including cannabis, alcohol, sedatives, stimulants, and polydrug combinations.
❌ Standardized Field Sobriety Tests (SFSTs)
Originally designed and validated for alcohol impairment. The HGN (Horizontal Gaze Nystagmus) test is a partial predecessor — but it captures only one biomarker and is subject to significant officer-to-officer variability. Not validated for cannabis, sedatives, or stimulants as standalone evidence.
❌ Blood & Saliva THC Testing
Measures exposure — not impairment. Per-se THC limits (like a BAC limit) are scientifically indefensible because the dose-impairment relationship is nonlinear, highly individual, and tolerance-dependent. NHTSA explicitly acknowledges that "presence ≠ impairment."
✓ Why Eye Movements Work for All Substances
Oculomotor control is one of the most distributed neural networks in the human brain — integrating the frontal cortex, cerebellum, brainstem, basal ganglia, and vestibular system. Every major class of impairing substance — alcohol, cannabis, opioids, benzodiazepines, stimulants — produces measurable, substance-specific disruptions in eye movement biomarkers. These cannot be consciously controlled or masked.
✓ Modern VOG Changes the Sensitivity Equation
Early oculomotor research used 1980s analog electrooculography with poor resolution. Modern Video-Oculography (VOG) achieves resolution of 0.05–0.1°, accuracy of 0.5°, and frame rates of 500–2,000 Hz — catching disruptions that older technology simply couldn't detect.
A Three-Layer Roadside Protocol
Defensible impairment detection requires multiple independent lines of evidence. ClearGazeTest anchors Layer 2 — objective functional impairment — which is the most scientifically robust and legally durable component.
- Driving pattern observation and incident context
- Rapid symptom screen: confusion, affect, response delay
- Alcohol breath test (critical — co-use is operationally common)
- Officer SFST observations documented for record
- Saccadic latency, velocity, and accuracy
- Smooth pursuit gain and corrective saccade frequency
- Pupillary constriction velocity and re-dilation slope
- Convergence accuracy and fixation micro-instability
- Contrast sensitivity and scotopic visual threshold
- Oral fluid THC (best operational compromise for recency)
- Tear-based cannabinoid mass spectrometry — reflects active exposure, not residual
- Blood THC (strong lab confirmation, used as secondary evidence)
- Alcohol BAC (integrated with Layer 1)
Why Eye Movements Are Impairment's Fingerprint
Oculomotor control integrates the frontal eye fields, parietal cortex, cerebellum, brainstem nuclei, basal ganglia, vestibular system, and retinal contrast processing — one of the most distributed and metabolically sensitive neural networks in the human brain.
Even small cortical disruptions produce measurable changes in eye movement parameters. Critically, different substances produce different biomarker signatures — allowing pattern analysis that points toward the category of impairment, not just that impairment is present.
Cannabis-Specific Eye Findings (Modern VOG)
THC's CB1 receptor activation in the cortex, cerebellum, and retina produces:
- 📍 Increased saccadic latency (slowed initiation)
- 📍 Reduced smooth pursuit gain (tracking degradation)
- 📍 Reduced contrast sensitivity (30–50%)
- 📍 Scotopic (low-light) visual impairment
- 📍 Abnormal pupillary light reflex dynamics
- 📍 Delayed ganglion cell transmission (ERG-confirmed)
How Detection Methods Compare
Not all impairment detection methods are equal in evidentiary value, operational practicality, or scientific validity. Here's how current approaches stack up for cannabis specifically.
| Detection Method | Measures Impairment | Cannabis-Specific | Court-Defensible |
|---|---|---|---|
| 🍺 Breathalyzer (BAC) | Yes | No (alcohol only) | Yes |
| 🩸 Blood THC Level | Poor correlation | Yes | Exposure only |
| 💧 Saliva THC Test | No | Yes | Recency only |
| 👮 SFST (Alcohol-based) | Alcohol only | Not validated | Challenged often |
| 👁️ ClearGazeTest (Oculomotor) | Yes — all substances | Yes + pattern ID | Objective biomarkers |
| 💧 Tear Cannabinoid (LC-MS) | Active exposure | Yes — accurate recency | Mass spec confirmed |
On tear-based cannabinoid detection: Research from Boston University and IMMAD has demonstrated that tears — a lipid-rich matrix — capture THC more reliably than saliva or breath. Non-invasive microcapillary swab collection combined with LC-MS quantification provides a biological marker of active exposure (not days-old residual), supporting causal inference that measured impairment is cannabis-related. This represents a meaningful advance over current oral fluid testing.
Built to Hold Up in Court
Objective biomarker data is the cornerstone of evidentiary durability. ClearGazeTest is designed with prosecutorial and judicial scrutiny in mind from the ground up.
Built for the Entire Traffic Safety System
ClearGazeTest serves every part of the impaired driving response chain — from the roadside stop to the courtroom.
Officers and Drug Recognition Experts (DREs) gain a rapid, standardized objective tool that augments and documents their roadside assessment. ClearGazeTest data travels with the arrest record and substantially strengthens what the officer observed with quantified neurological evidence.
Prosecutors receive a timestamped, device-generated biomarker report — not officer notes. Defense challenges to subjectivity become much harder to sustain when the core evidence is a 12-parameter objective neurological assessment grounded in published science.
State and federal traffic safety programs gain a population-level data tool — understanding the true prevalence and severity of cannabis and polydrug impairment in their jurisdiction, informing resource allocation, training priorities, and legislative advocacy for updated per se standards.
What Law Enforcement Actually Asks
Implied consent laws vary by jurisdiction. In many states, refusal to submit to chemical testing (blood, breath) is admissible as evidence of guilt. The status of eye-based oculomotor assessment under implied consent frameworks is jurisdiction-specific and evolving as the technology is adopted. Contact us to discuss the specific legal framework in your state and how the assessment protocol should be documented.
The platform includes a pre-assessment screening protocol that flags known conditions affecting oculomotor function (strabismus, nystagmus, neurological conditions). When flagged conditions are present, the assessment output includes appropriate clinical caveats. The 12-biomarker approach provides redundancy — an individual biomarker affected by a medical condition is contextualized by the other 11. Assessment reports are designed to be interpreted by a qualified clinician, not used as standalone arrest evidence.
The ClearGazeTest protocol is designed for administration by trained law enforcement and clinical personnel. Officer training covers standardized device operation, pre-assessment screening, proper documentation, and chain-of-custody procedures for the data output. Training time is significantly shorter than full DRE certification, and the platform's standardized interface reduces between-officer variability — one of the key advantages over subjective field evaluations.
Yes — and this is one of the most operationally important capabilities. Alcohol and cannabis together produce additive or synergistic impairment, and this combination is increasingly common in crash investigations. ClearGazeTest's biomarker pattern analysis is sensitive to polydrug impairment and does not require knowing which substances are present before testing — the pattern emerges from the data.
Assessment data is encrypted, timestamped, and stored on secure servers with full audit trail logging. Reports are generated in formats compatible with law enforcement case management systems and can be produced in discovery. Chain-of-custody documentation follows established digital evidence standards. Data integrity is maintained from the moment of assessment through court presentation. Contact us for details on your jurisdiction's specific requirements.
ClearGazeTest is available for departmental and state-level pilot programs through NeuroClear's law enforcement partner program. Use the contact form below to describe your jurisdiction, agency size, and specific needs. A representative will follow up to discuss pilot design, officer training, data management setup, and evidentiary framework considerations in your state.
Bring Objective Impairment Detection
to Your Jurisdiction
For law enforcement agencies, state traffic safety offices, prosecutors, and training academies — let's discuss how ClearGazeTest fits your operational needs.